Relay Therapeutics Inc (RLAY)
4.75
+0.11
(+2.37%)
USD |
NASDAQ |
Nov 22, 16:00
4.74
-0.01
(-0.21%)
After-Hours: 20:00
Relay Therapeutics Enterprise Value: -44.54M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | -44.54M |
| November 21, 2024 | -62.95M |
| November 20, 2024 | -59.60M |
| November 19, 2024 | -36.17M |
| November 18, 2024 | -21.11M |
| November 15, 2024 | 14.88M |
| November 14, 2024 | 97.74M |
| November 13, 2024 | 132.89M |
| November 12, 2024 | 154.65M |
| November 11, 2024 | 191.47M |
| November 08, 2024 | 198.17M |
| November 07, 2024 | 188.12M |
| November 06, 2024 | 206.53M |
| November 05, 2024 | 156.32M |
| November 04, 2024 | 139.58M |
| November 01, 2024 | 137.91M |
| October 31, 2024 | 100.80M |
| October 30, 2024 | 113.31M |
| October 29, 2024 | 145.02M |
| October 28, 2024 | 166.72M |
| October 25, 2024 | 165.05M |
| October 24, 2024 | 193.42M |
| October 23, 2024 | 211.78M |
| October 22, 2024 | 271.86M |
| October 21, 2024 | 233.47M |
| Date | Value |
|---|---|
| October 18, 2024 | 283.54M |
| October 17, 2024 | 268.52M |
| October 16, 2024 | 295.22M |
| October 15, 2024 | 285.21M |
| October 14, 2024 | 286.88M |
| October 11, 2024 | 295.22M |
| October 10, 2024 | 258.51M |
| October 09, 2024 | 230.13M |
| October 08, 2024 | 203.43M |
| October 07, 2024 | 218.45M |
| October 04, 2024 | 250.16M |
| October 03, 2024 | 243.49M |
| October 02, 2024 | 243.49M |
| October 01, 2024 | 253.50M |
| September 30, 2024 | 341.95M |
| September 27, 2024 | 555.52M |
| September 26, 2024 | 545.51M |
| September 25, 2024 | 488.82M |
| September 24, 2024 | 527.17M |
| September 23, 2024 | 550.52M |
| September 20, 2024 | 562.19M |
| September 19, 2024 | 622.22M |
| September 18, 2024 | 575.53M |
| September 17, 2024 | 578.86M |
| September 16, 2024 | 663.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-70.42M
Minimum
Oct 25 2023
4.854B
Maximum
Jan 22 2021
1.496B
Average
1.301B
Median
Enterprise Value Benchmarks
| Pfizer Inc | 202.30B |
| Summit Therapeutics Inc | 13.55B |
| Biomarin Pharmaceutical Inc | 11.91B |
| Lexicon Pharmaceuticals Inc | 153.64M |
| Arbutus Biopharma Corp | 537.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -88.10M |
| Total Expenses (Quarterly) | 96.37M |
| EPS Diluted (Quarterly) | -0.63 |
| Earnings Yield | -54.95% |
| Normalized Earnings Yield | -56.80 |